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Thrombolytic treatment with plasmin or plasminogen acti-
vators is meant to lyse thrombi and to recanalize a blood
vessel or catheter. The target thrombus can emerge in differ-
ent locations such as the deep veins of the leg (leading to deep
venous thrombosis), in the lung artery (pulmonary embo-
lism), and in arteries in the heart, brain (stroke), or leg, and
can block bypass grafts or dialysis catheters.
The target thrombi can be of different composition and
age, as documented in samples obtained by thrombectomy.
With myocardial infarction (MI), it has been reported that
nearly 50% of thrombi are older than 24 hours,1 and it has
been described that 9% of thrombi are older than 5 days.2 This
implies a quite wide spectrum in the composition of thrombi
and a reduced accessibility when reendothelialization has
progressed in the presence of matured thrombi. It is now
evident that acute myocardial infarction (AMI) refers to the
acute clinical symptoms and not necessarily to completely
acutely formed fresh thrombi.
In addition, the obstruction is not always a fully ﬁbrin-
based clot. The recognition of extracellular leukocyte net-
works with nucleotide strands in ﬁbrin clots implies the need
of DNA-ase to contribute to the lysis of such networks.3–5
These reﬁnements in knowledge of the target thrombus,
mainly established for AMI, might provide clues for the
observed apparent ceiling in recanalization rate (around
80–90%) that can be achieved by lysis strategies6 and count
in favor of mechanical methods which can achieve higher
patency rates.
Keywords
► thrombolysis
► systemic effects
► bleeding risk
Abstract Thrombolytic therapy involves thrombolytic agents administered to patients suffering
from venous or arterial thrombosis. The therapy induces systemic effects interrelated
with the thrombolytic agent used. Bleeding is a prominent complication of thrombolytic
therapy. Exhaustion of coagulation factors, generation of excessive amounts of ﬁbrin
degradation products (FDPs), therapy-induced activation of coagulation, therapy-
induced anticoagulation, and formation of new ﬁbrin all illustrate the complexity of
effects of the treatment and challenges the hemostatic balance in the patients. The
therapy-induced effects can be modulated by parallel administration of anticoagulants.
Risk assessment is mandatory prior to thrombolytic therapy. Anticoagulated and
unconscious patients represent particular safety concerns, and should be fully evaluat-
ed. Several guidelines describe the choice of tests and their safety limits in relation to
pretreatment evaluation of anticoagulated patients. Fibrinogen depletion and FDPs
during treatment may be promising markers for the evaluation of bleeding risk
posttreatment. Future risk assessment measures should focus on the dynamics of
the hemostatic balance. Here, thromboelastography may be considered a tool address-
ing clot formation, ﬁbrin structure, and ﬁbrinolytic resistance in parallel. Suitable
laboratory analysis performed shortly after treatment may help to recognize severe
treatment-induced systemic effects that can be counteracted by rational treatment,
thereby reducing bleeding risk.
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Related to the above-mentioned insights, in more recent
years the single biological treatment with the thrombolytics
for AMI has become less used and has been replaced to a large
extent by mechanical methods of percutaneous coronary
intervention (PCI), aspiration of thrombi, and combinations
of lysis and mechanical strategies.
The present review concerns the safety associated with
thrombolytics, used either alone or as treatment component.
We focus on AMI and stroke, but all thrombolytic treatments
have in common a depletion of internal hemostatic factors
(systemic effects), anticoagulation, and a risk of bleeding
associated with that systemic effect.
From evaluation of mechanisms and large interindividual
variability in treatment and systemic response, it is suggested
to select laboratory methods for the monitoring of systemic
effects and the consequences in hemostasis for individuals to
predict bleeding and importantly to rationally assist in man-
agement of bleeding, which irrevocably will affect a subset of
patients undergoing thrombolytic treatment.
Mechanisms of Thrombolytics
Thrombolytics that have frequently been studied comprise
alteplase (recombinant tissue-type plasminogen activator
[rt-PA]), urokinase (urinary-type plasminogen activator,
both in active and proform), reteplase (which is part of
tissue-type plasminogen activator [t-PA], K2P, with reduced
clearance rate), and tenecteplase (a geneticallymodiﬁed t-PA,
possessing improved ﬁbrin speciﬁcity and reduced inhibition
by plasminogen activator inhibitor).
It has been well recognized that rapid lysis of thrombi by
exogenously provided thrombolytics is a forced situation to
achieve rapid lysis. The dosages of thrombolytics used are
therefore very high comparedwith plasma levels of endogenous
plasminogen activators. One of the premises for the high dose is
that plasminogen activators incorporated into the thrombus
during thrombus formation are far more effective than plasmin-
ogen activators deployed after thrombus formation. Further-
more, a t-PA dose in the high range has been selected in practice
to be effective also with respect to older and organized clots.
The difference in concentration of lytic agents for endoge-
nous and exogenous lysis has been illustrated by in vitro
experiments showing that a 20 to 40 times higher concentra-
tion of t-PA is needed for exogenous lysis compared with
endogenous lysis.7,8 Accordingly, levels of t-PA during throm-
bolysis reach 1 to 2 µg/mL, while endogenous free active t-PA
in resting condition is around 1 ng/mL9 and reaches 10 ng/mL
extra t-PA in plasma after exhaustive exercise,10while locally
endothelial stimulation can deliver 2 to 4 ng/min  L tissue to
be incorporated in forming thrombi.11
Mechanisms of Systemic Effects
Systemic effects have various origins as depicted in►Fig. 1,12
and will be discussed here.
Systemic effects are mainly an issue of thrombolytic
treatment due to the very high dosages used, as discussed
earlier, where the ﬁbrin speciﬁcity is not maintained.
History documents that the thrombolysis originally
performed by predominantly streptokinase therapy was
accompanied by adverse effects, involving severe systemic
reductions of ﬁbrinogen, plasminogen, and plasmin inhib-
itor.13 The developments of newer thrombolytics were
largely focused on improving ﬁbrin speciﬁcity and reducing
systemic effects. The thrombolytic agent evaluated exten-
sively after streptokinase and urokinase was t-PA, and the
reduced systemic effects of t-PA have been convincingly
documented in the ﬁrst head-to-head comparisons of
streptokinase and t-PA.13 Treatment with t-PA induces
less proteolysis of ﬁbrinogen, factor VIII, and factor V
than induced by streptokinase.
Several aspects of the mechanisms of systemic effects
can be recognized. Plasminogen activationwithout ﬁbrin is
a well-known phenomenon for streptokinase, but also
for urokinase and prourokinase,14,15 while it is less so for
t-PA. The mutated t-PAs (reteplase and tenecteplase) show
further reduction in systemic effects. The bat vampire
plasminogen activator is reported to be the most favorable
in this respect.16 These effects are studied with puriﬁed
thrombolytics and components.17,18 In a plasma system,
the presence of stimulating factors such as ﬁbrin degrada-
tion products (FDPs) interferes with conclusions about
mechanisms.
Next to the speciﬁc characteristics of a thrombolytic, the
ﬁbrin-independent effect is also strongly dependent upon
dosages of the thrombolytics. Anno 2016, the systemic effect
with current treatments is still too large and undesired and
more ﬁbrin-speciﬁc agents remain desired.19,20
Fig. 1 Scheme of systemic effect origins. Systemic effects can be due
to effects of thrombolytics without ﬁbrin, effects stimulated by ﬁbrin
degradation products (FDPs) from the primary thrombus, and from
clots/ﬁbrin originating from reactive coagulation following
thrombolysis.12
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Fibrin Degradation Products’ Effects
The concentrations of FDPs and large soluble ﬁbrin polymers
are elevated in patients with acute thrombotic diseases.
However, already in normal individuals these factors are
present and constitute soluble stimulating factors for plas-
minogen activation by t-PA. This was elegantly demonstrated
by a chromogenic assay based on stimulation of t-PA activity
showing in normal volunteers a level of 3 µg ﬁbrinogen/
ﬁbrin equivalents/mL of “soluble ﬁbrin.”21 During thrombo-
lytic treatment, these levels can increase 5- to 10-fold and are
supposed to not represent the small primary thrombus as
main source.22 This latter assumption is based on calculations
of the size of thrombi and expected amounts of FDPs and on
experiments showing generation of FDPs upon incubating
plasma with a lytic agent, and provided evidence for “new”
FDP generated by an ongoing coagulation processes during
thrombolytic treatment.22 The stimulation is predominantly
from fragments containing D and E fragments (DDE),23which
are normally included in so-called D-dimer assays and in
assays employing the E-domain for catching or tagging.24,25
Major Effects and a Threshold
Very large off-target effects of plasmin can occur, and are due
to the situation that the inhibitory capacity for plasmin in
plasma is not sufﬁcient to achieve a rapid neutralization of all
plasmin that can be formed. The level of plasminogen is
around 2 µM in normal human plasma, while the level of
rapidly acting plasmin inhibitor (the plasminogen-binding
form) is only 0.7 µM.26 This rapid plasmin inhibitor exerts one
of the fastest biological interactions addressing non–ﬁbrin-
bound plasmin.27 After this very effective inhibitory barrier,
the inhibition by the non–plasminogen-binding plasmin
inhibitor (0.3 µM) and by α-2-macroglobulin (2 µM) is slower.
The slower inhibition allows plasmin, as broad-spectrum
protease, to also proteolyze other proteins more effectively.
In hemostasis, the well-known “victims” after ﬁbrinogen are
von Willebrand factor,28 factor VIII,29,30 and factor V and
Va,31–33 all shown to be sensitive to plasmin. Also factor IX
and factor X are plasmin sensitive,34,35 and to a minor extent
factor XIII.36–38 The formation of large ﬁbrin and ﬁbrinogen
degradation products with the capacity to stimulate in solu-
tion t-PA-induced plasminogen activation occurs predomi-
nantly after passing the highly effective inhibitory barrier of
plasminogen-binding plasmin inhibitor and can be counter-
acted by providing additional plasmin inhibitor.39
Itmaybe clear thatdegradationof clotting factors: (1) impairs
coagulation, (2) that formed ﬁbrin and ﬁbrinogen degradation
products that impair ﬁbrin polymerization and stimulate plas-
min formation in solution, and (3) that the exhaustion of
ﬁbrinolysis inhibitors facilitate lysis of clots. This renders sys-
temic effects an important determinant of the risk of bleeding. It
is of importance to recognize that systemic effects are quite
different among patients. Residual ﬁbrinogen analysis illustrates
this aspect clearly for t-PA treatment (see ►Fig. 213), demon-
strating residualﬁbrinogen concentrations in averybroad range.
It can be concluded that one important issue regarding
selection of improved thrombolytics is related to reduction of
systemic effects. In addition, variable susceptibility among
individuals may call for laboratory diagnostic testing to both
recognize susceptible patients and identify the actual con-
sequences of systemic adverse effects.
Evaluation of the Ratio between Thrombolysis and
Systemic Effects
In early phases of development of a new thrombolytic, its
dose-dependent efﬁcacy and side effects can be documented
in detail with specialized laboratory methods. This has been
done in the past for agents including streptokinase, APSAC
(anisoylated plasminogen streptokinase activator complex),
t-PA, urokinase prourokinase, reteplase, tenecteplase, des-
moteplase, and (micro)plasmin, and is still ongoing for new
agents and treatment modulation. Such a new agent is a
mutant of pro-u-PA which upon activation is speciﬁcally
more strongly inhibited by C1-inactivator, reducing its non-
ﬁbrin impact40. A treatment modality that mimics endoge-
nous synergy between t-PA and prourokinase using
combination treatment is also an option, although it is less
well explored, to increase ﬁbrin speciﬁcity.19
In Vitro Dose Finding
In vitro methods for efﬁcacy concern typically clot lysis tests
by an exogenously provided thrombolytic, involving, for
instance, hanging clot and Chandler loop principles.41,42
The methods for evaluation of side effects can be used in a
combination of the same tests by evaluation of non–clot-
bound actions in the surrounding blood or plasma. This can
also be done by incubation of plasma with the thrombolytic
agent. Such tests can include assays of plasminogen consump-
tion, residual rapid plasmin inhibitor, formation of plasmin–
plasmin inhibitor complexes, plasmin–α-2-macroglobulin
complexes, and formation of FDPs, and proteolysis of ﬁbrino-
gen to its Bβ 1–42 fragments and degradation/inactivation of
factor VIII, factor V, and vonWillebrand factor. An interesting
option arises from the availability of an assay speciﬁc to
ﬁbrinogen degradation products reporting off-target proteo-
lytic action of plasmin on ﬁbrinogen.24
The in vitro ratio ﬁbrin speciﬁcity/efﬁcacy and side effects
(systemic effects) can be documented for different dosages
Fig. 2 Categories of patients with different residual ﬁbrinogen after t-
PA treatment. Data taken from Collen et al.13
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and benchmarked with rt-PA. It can be used to support the
selection of dosages for treatment and positioning of the new
thrombolytic agent relative to existing ones.
In dose-ﬁnding studies in individuals, the same assays can
be applied for the systemic effects (provided the sample is
stabilizedwhen necessary by addition of inhibitors). It should
be noted, as discussed earlier, that laboratory studies on FDPs
for analysis of the lysis of pathological thrombi (unless
massive) are not options for efﬁcacy in patient treatment
(see discussion later). Here, recanalization and eventually
survival and risk of reinfarction are the relevant end points.
Dynamics of Lysis and Coagulation in the
Patients during Thrombolysis
Treatment-Induced New Fibrin Formation
Lysis of an occluding thrombus is expected to result in
reperfusion and in uncovering thrombogenic surfaces, and
potentially the thrombolytic is involved in removing hemo-
static ﬁbrin clots or counteracting new formation of hemo-
static clots. Activation of the coagulation mechanism not only
is plausible, but also has been documented to occur during
thrombolysis (see the discussion later). Accordingly, in vivo,
the lysis of the thrombus with a thrombolytic is not a linear
process of lysis, but involves also a feedback activation of
coagulation and formation of newclots. Thus, lysis has to cope
with existing and newly formed ﬁbrin due to the treatment.
This new coagulation effect can contribute to reocclusion and
eventually reduced efﬁcacy of the treatment. This dynamic
process of treatment-induced coagulation is well recognized
in MI (also coined as thrombolytic paradox) and is docu-
mented in animal models where experimental clots show
lysis and growth.43 Treatment-induced coagulation is also
documented in MI patients by the generation of coagulation
activation products such as prothrombin fragment 1 þ 2
(thrombin generationmarker), thrombin–antithrombin com-
plex (thrombin presence marker), and ﬁbrinopeptide A
(thrombin action marker). A consequence is that the concen-
tration of FDPs is much higher than can be expected from the
existing thrombus due to substantial contribution from the
additional lysis of the newly formed ﬁbrin. The treatment-
induced coagulation and the prothrombotic condition of the
infarcted area, in combination with the apparent prothrom-
botic phenotype of the infarct patient, can result in reocclu-
sion of the target vessel. The coagulation process involved can
be modulated by the use of inhibitors such as heparins and
platelet inhibitors, which are carefully selected and evaluated
for effect and steady companions in the thrombolytic treat-
ment ofMI and under investigation for stroke, and still subject
of research to improve effects.44 The treatment-induced
coagulation is related to the speciﬁc thrombolytic, the dosage,
and way of administration. As an example, this is illustrated
by differences in generated activation markers of coagulation
when comparing infusion and bolus (►Fig. 3).45,46
Modulation of Treatment-Induced Coagulation
Treatment-induced coagulation can be modulated by inhibi-
tion of coagulation in parallel with the administration of the
thrombolytic agent. Initially, heparin and/or antiplatelet
agents were used as modulators in patients with MI. Current
recommendations include adjuvant regimens with enoxa-
parin, unfractionated heparin (UFH), and fondaparinux.47
Evaluation of rt-PA combined with platelet glycoprotein
IIB–IIIA inhibitors is still under study for stroke.48,49
More recent approaches also include the possibilities of
the inhibition of contact activation, factor XI action, thrombin
inhibition, and TAFI (thrombin-activatable ﬁbrinolysis inhib-
itor) inhibition. It has been recognized that thrombus stabili-
zation follows activation of the intrinsic system (factor XII,
prekallikrein, and in particular factor XI), while the thrombin
formed by this route activates TAFI, which is an inhibitor of
ﬁbrinolysis and retards clot lysis.50 This is expected to have
Fig. 3 Molecular markers during and after treatment with bolus t-PA (four boluses in 1 hour) and infusion of t-PA for a total of 6.5 hours for
patients showing recanalization. Data are from the study of Andreotti et al,46 and medians and standard errors are plotted.
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contributed to stabilization of the culprit thrombus in infarct-
related areas and is operational indeed for the initial throm-
bus, as suggested by increases in factor XIa–C1-inactivator
complex51 and by the thrombotic effects in experimental
studies in factor XII– or prekallikrein-depletedmice, in case of
inhibitors of factor XIIa (mice and rat model),52 in case of
inhibition of factor XI in mice and rabbit models,53 and by
XIIa and XIa inhibition in extracorporeal circulation and
grafts.54,55
Speciﬁc options for modulation of treatment-induced
coagulation may be targeted at TAFI because of positive
reports showing that, in TAFI-deﬁcient mice, venous thrombi
are smaller and TAFI polymorphism inﬂuences stroke bur-
den.56 TAFI inhibition shows less microthrombosis57 and
ﬁbrin deposition in the lung in experimental models,58 and
it induces more lysis in a rabbit model51 and potentiates
jugular vein lysis.59
The occurrence of this mechanism of thrombus stabiliza-
tion via the intrinsic route is likely to operate also in the new
thrombolytic-induced coagulation. Some experimental
evidence is provided from increases during thrombolysis in
activated factor XII60,61 and in cleaved high-molecular-
weight kininogen.60,62,63 Interestingly long-lasting depletion
of the FXII-dependent pathway of ﬁbrinolysis has been
reported in patients undergoing thrombolytic therapy with
rt-PA, thereby carrying an increased risk of early reinfarc-
tion.64 More thorough documentation is warranted, and
based on such observations regarding the role of the contact
system and TAFI, new adjuvant treatment may arise in the
near future.65
A focusedway tomodulate treatment-induced coagulation
could be by inhibition of TAFI formation or TAFI directly.66,67
TAFI participation requires thrombomodulin, which will be a
major co-determinant. Inhibition of thrombin and subse-
quent TAFI formation by the use of argatroban indeed stim-
ulates lysis.68
Systemic Effects during Treatment
Of importance is that the systemic effects are stimulated by
lysis of the thrombus, which results in the formation of large
FDPs that show stimulatory action for t-PA.23 Paradoxically,
the larger the effects of the ﬁbrinolysis target (existing þ
newly formed thrombi), the larger the systemic effects may
become.
The systemic effects reduce the quality of newly formed
ﬁbrin clots by several mechanisms:
• The amount of ﬁbrinogen is reduced, whichmay result in a
smaller clot.
• Fibrin and ﬁbrinogen degradation products disturb ﬁbrin
polymerization and cause a change in ﬁbrin structure.69
• Reduced coagulation results in impaired cross-linking
(factor XIII) and reduced inhibitor formation (TAFI
activation).
In addition, the anticoagulant used to prevent reactive
coagulation during and after treatment adds to impairment
of coagulation activation and consequently the risk of
bleeding.
The complex situation in vivo during thrombolysis and the
application of different thrombolytics and regimen with
anticoagulation lead to a set of rules about systemic effects.
Reduced systemic effects link with:
• Inhibition of rethrombosis and reducing treatment-
induced clot formation
• Fibrin speciﬁcity of the lytic agent asmoreﬁbrin speciﬁcity
causes less systemic effect by ﬁbrin-independent effects,
by low circulating soluble ﬁbrin and by low large ﬁbrin
(ogen) breakdown products
Increased systemic effects link with:
• Larger thrombi and a strong prothrombotic phenotype of
the patient
• Higher dosage of a thrombolytic or prolonged infusion
schemes
• Coagulation inhibition targeting at the intrinsic pathway,
which gives more/faster lysis
Thus, treatment with thrombolytics requires strategies
reducing the treatment-induced activation of coagulation,
thereby further decreasing the bleeding risk. For assessment
of bleeding risk, two lines could be followed: (1) evaluation of
the patient before treatment for risk factors for bleeding and
(2) evaluation of the patient after completion of treatment for
risk of posttreatment bleeding.
Identiﬁcation of Patients for Thrombolysis:
Risk Assessment
Major bleeding is still a signiﬁcant problem of thrombolytic
therapy, despite the development of ﬁbrin-speciﬁc drugs. For
all thrombolytics available today, there are to a certain extent
systemic adverse effects of which hemorrhagic stroke is
considered the most feared complication. Thrombolytic
agents that are presently available do not have the capability
to distinguish between pathological thrombi and normal
hemostaticﬁbrin plugs. The riskof hemorrhagic stroke ranges
from 1 to 7% depending on the target organ of the thrombo-
lytic agent.70–72 The current scope for use of intravenous
thrombolytic agents is thrombotic stroke, STEMI (ST segment
elevation myocardial infarction), pulmonary embolism, and
to a lesser extent vein thrombosis. Because of the high
treatment-induced bleeding risk, major efforts should be
undertaken to exclude patients who have a higher risk for
bleeding. It should be noted that only alteplase is FDA
approved for thrombolysis of thrombotic stroke. Also, it
should be noted that the primary treatment of STEMI is
PCI and that thrombolytic treatment of non-STEMI is not
indicated.
The efforts to reduce the bleeding risk in thrombolytic
therapy have resulted in recommendations on absolute con-
traindications. Such recommendations are based on clinical
information or biochemical measures. ►Table 173 summa-
rizes the hemostasis contraindications.
Also, it is recommended to perform biochemical tests to
help guide whether the patients are eligible for thrombolytic
therapy (►Table 273).
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Laboratory Tests (Pretreatment)
Identiﬁcation of patients at risk of bleeding prior to throm-
bolytic therapy is mandatory to ensure the safety of the
treatment. Patients subjected to thrombolytic therapymostly
have a prothrombotic phenotype andwill not generally suffer
from inherited bleeding tendency, that is, coagulation factor
deﬁciencies and platelet disorders. The majority of patients,
however, may have an acquired bleeding risk due to antico-
agulant treatment, that is, heparins, vitamin K antagonists
(VKAs), and direct oral anticoagulants (DOACs; being direct
thrombin inhibitors [dabigatran, argatroban] and direct or
indirect inhibitors of FXa [rivaroxaban, apixaban, fondapar-
inux]). Particular problems are related to unconscious
patients who are possibly on treatment with DOACs, as tests
to exclude use of DOACs are not widely available in routine
laboratories. However, to ensure the safety of the treatment,
the laboratory analysis repertoire should identify these con-
ditions before thrombolytic therapy is initiated.
According to international guidelines, global tests such as
the prothrombin time (PT) and the activated partial pro-
thrombin time (aPTT) may be particularly useful for identiﬁ-
cation of patientswith increased riskof bleeding, while ruling
out patients receiving low-molecular-weight (LMW) heparin
and to some extent DOACs that require more speciﬁc
tests.73–75 Quick access to relevant laboratory results is
important for the visitation of patients for and on thrombo-
lytic therapy. Hence, point-of-care test (POCT) devices are
advantageous for laboratory testing in the thrombolytic
setting, because the turnaround time of the tests is short
and the analysis can be performed at bedside. Guidelines
focusing on the preanalytical and analytical conditions of the
assay procedures should be followed to ensure that the
outcome of the analytical work is reliable.75–77
Testing for Vitamin K Antagonists
The test of choice ruling out VKA treatment is the PT
addressing the coagulation capacity of the tissue factor–
induced (extrinsic) and common coagulation pathway. A
variety of PT assays and applications are available, and the
PT can be reliably performed using POCT devices.78,79 The
outcome of the analysis can be expressed in seconds, ratio,
and international normalized ratio (INR).80 Ischemic stroke
patients on VKA treatment with INR < 1.7 can safely be
treated with intravenous rt-PA.73,81,82 PT values below
15 seconds are also considered safe,73 but it should be noted
that the clotting time of the PT depends on the assay con-
ditions and the equipment used for analysis. Thus, a PT safety
limit expressed in seconds is not recommendable.
Testing for Heparins
The aPTT addresses the coagulation capacity of the surface-
induced (intrinsic) and common coagulation pathway. The
aPTT is sensitive to UFH. Only few POCT devices capable of
measuring aPTT are presently available83–85 and their perfor-
mance in a thrombolytic setting has not been evaluated so far.
The outcome of the aPTT can be expressed in seconds or ratio.
An aPTT ratio within the reference range of the assay prior to
thrombolysis is considered as safe,73whereas other guidelines
recommend a safety range of the aPTT ratio as  1.5 times the
baseline value.74 It is, however, not clear how this baseline
value is deﬁned. It should be noted that the aPTT is not suitable
for detection of LMW heparin or fondaparinux, which should
be determined with anti-FXa assays.75
Testing for Direct Oral Anticoagulants
Treatment with direct thrombin or FXa inhibitors may prolong
the PT and aPTT, but these measurements are not reliable for
measuring the pharmacokinetic or pharmacodynamic effects of
DOACs. The aPTT, however,maybeused to screen for presenceof
dabigatran and rivaroxaban, but the aPTT is unsuitable to
determine the concentration of the drugs. A normal aPTT cannot
exclude the presence of dabigatran in some patients, and both
the PT and aPTT are insensitive to apixaban.
The thrombin time (TT) and ecarin clotting time (ECT) are
both sensitive to the presence of direct thrombin inhibitors,
and normal clotting times with these tests suggest very low
plasma levels of these drugs. Studies have suggested using the
combination of TT and aPTT measurements as a safety indica-
tor prior to thrombolysis.86 It is, however, recommended that
dilute thrombin-based assays, ECT-based assays, or chromo-
genic anti-IIa assays should be used for determination of
Table 2 Biochemical measures to guide eligibility of patients
for thrombolytic therapy
Blood glucose
Oxygen saturation
Electrolytes/EGFR/creatinine
Complete blood count, including platelets
Prothrombin time (PT)
Activated partial thromboplastin time (aPTT)
Electrocardiography (ECG)
Troponins
Abbreviation: EGFR, estimated glomerular ﬁltration rate.
Source: adapted from Jauch et al.73
Table 1 Clinical information to decide eligibility of patients for
thrombolytic therapy
• Time from stroke symptoms  4.5 h
• Time from MI symptoms  24 h
• Previous intracranial hemorrhage or stroke of
unknown origin
• Blood pressure > 185/110 mm Hg after two attempts to
reduce blood pressure
• Active gastrointestinal bleeding within 1 mo
• Surgery and trauma within 14 d
• Noncompressible punctures within 24 h
(liver biopsy, etc.)
• Ischemic nerve system/neoplasms/known atrioventricular
malformation
• Current use of warfarin INR > 1.7
• Current use of direct thrombin or factor Xa
inhibitors (DOACs)
Abbreviations: DOACs, direct oral anticoagulants; INR, international
normalized ratio; MI, myocardial infarction.
Source: Adapted from Jauch et al.73
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dabigatran, whereas chromogenic anti-Xa assay should be
used for determination of direct Xa inhibitors such as rivarox-
aban. A variety of speciﬁc chromogenic anti-IIa and anti-Xa
assays are available for measurement of DOACs,83,87–92 and
several of these assays are available as POCT. It is of particular
note that all assays should be calibrated with drug-speciﬁc
calibrators. A thorough and comprehensive guideline describ-
ing themeasurement of DOACs has been published recently.75
Recent guidelines state that patients treated with DOACs
should not be subjected to thrombolytic therapy with rt-PA
unless the aPTT, PT, and platelet count are normal. Moreover,
safe treatment with rt-PA requires that the ECT, TT, or
appropriate direct FXa activity assays are normal, or that
the patient has not received a dose of DOACs for >2 days.73
This recommendation, however, is rather weak (class III; level
of evidence C) and further research is needed to consolidate
the safety limits of DOACs. The recommended tests and safety
limits in anticoagulated patients are listed in ►Table 3.
Thromboelastography (TEG) and rotational thromboelas-
tometry (ROTEM) are promising tools to investigate the
anticoagulant effect of DOAC as demonstrated by in vitro
studies,93 and the techniques can also be used for detection of
factor deﬁciencies, presence of heparins, and VKAs. Clinical
trials focusing on apixaban and rivaroxaban have shown that
TEG may be a suitable tool for the determination of DOACs,
also in the thrombolytic setting,94,95 but the precision of the
assays in some cases is poor.96 More studies are needed to
reach ﬁrm conclusions regarding the usage of TEG and
ROTEM in relation to thrombolytic risk assessment.
Laboratory Tests (Posttreatment)
Reduction in the plasma concentration of ﬁbrinogen after
thrombolytic therapy is signiﬁcantly associated with risk of
posttreatment bleeding.97–100 A large clinical trial with more
than 500 patients receiving rt-PA as thrombolytic agent
demonstrated that a reduction in ﬁbrinogen of  2 g/L
from baseline to 6 hours after therapy increased the risk of
bleeding in the ﬁrst 72 hours after therapy more than four
times, and that the negative predictive value of ﬁbrinogen
depletion for any major bleeding was 94%.97 Another study,
assessing the ﬁbrinogen concentration before and 2 hours
after rt-PA therapy, showed that a reduction in ﬁbrinogen
concentration of 25% or more during therapy, or a ﬁbrinogen
concentration  2 g/L after therapy increased the bleeding
risk in the ﬁrst week after therapy more than seven times.98
For comparison, a study of patients subjected to rt-PA
treatment due to peripheral arterial or venous thrombosis
showed that the rate of major bleeding was signiﬁcantly
higher for patients with a ﬁbrinogen level  1.5 g/L.99
These studies demonstrate that plasma ﬁbrinogen levels
may serve as a posttreatment safety indicator of thrombo-
lytic therapy.
Coinciding with a nadir in ﬁbrinogen, treatment of stroke
or MI with rt-PA showed a peak in FDPs between 1 and 4
hours.37,101 Sampling at 2 hours after start of treatment
showed a relationship of FDP level with hemorrhage in
several studies.101–104 High FDPs at 24 hours was suggested
as contraindication for antithrombotic drugs in the ﬁrst 72
hours after stroke.102 These studies demonstrate that FDPs
levels may also serve as a posttreatment safety indicator of
thrombolytic therapy. It is suggested to further invest in
comparisons of FDP assays in view of the data (see later)
that DDE containing fragments are more active in systemic
activation.
It should be noted that anticoagulant therapy, irrespective
of the drug used, should not be initiated in stroke patients
within 24 hours of treatment with intravenous rt-PA.73
Conclusion and Future Options
The bleeding diathesis in thrombolysis treatment shows
similarities with bleeding diathesis in traumatic and post-
surgery situations. ROTEM or TEG analyses have been used in
these settings, andmay also be promising tools for evaluation
of the coagulation status prior and after thrombolytic
therapy.
Table 3 Recommendations of choice of tests and safety limits in patients receiving anticoagulant treatment prior to thrombolytic
therapy
Drug Recommended test Safety limit
Vitamin K antagonists Prothrombin time INR < 1.7
PT < 15 s
Unfractionated heparin Activated partial thromboplastin time Values within reference range
aPTT < 1.5  baseline
LMW heparin Anti-Xa assay Not applied
Fondaparinux Anti-Xa assay Not applied
Direct thrombin inhibitors
Dabigatran
Argatroban
Thrombin time
Ecarin clotting time
Chromogenic anti-IIa assay
Values within reference ranges
Last dosage > 2 d ago
Direct factor Xa inhibitors
Rivaroxaban
Apixaban
Chromogenic anti-Xa assay Values within reference ranges
Last dosage > 2 d ago
Abbreviations: aPTT, activated partial thromboplastin time; INR, international normalized ratio; LMW, low molecular weight; PT, prothrombin time.
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These analyses, performed at bedside and using whole
blood, show sensitivity toward most coagulation disorders,
platelet dysfunction, and presence of various anticoagulants.
We have previously demonstrated that ROTEM analysis prior
to surgery is predictive of intraoperative bleeding in an
orthognathic setting.105
Evaluation of ﬁbrinogen turnover during thrombolytic
therapy may be another option ensuring the safety of treat-
ment. Patients depleted in ﬁbrinogen during surgery and
identiﬁed with ROTEM or TEG analyses could be supple-
mented with ﬁbrinogen to prevent postsurgical bleeding,
according to the most recent guidelines from the European
Society of Anaesthesiology.106 In contrast, a Cochrane Data-
base Systemic Review concludes that currently only weak
evidence supports the use of ﬁbrinogen concentrate in bleed-
ing patients, tested in primarily elective cardiac surgery, and
that more research is urgently needed.107
A further advancement may be the application after
thrombolysis of amethod incorporating data on ﬁbrin quality
and lysis susceptibility. A complex phenotypic test reﬂecting
all elements of risk of bleeding in thrombolysis patients—
reduced clotting, reduced elasticity, increased sensitivity to
lysis programmed by low thrombin formation, and reduced
TAFI activation—and the interrelations might be a rational,
theoretical choice. To that end, it is possible to select a ROTEM
variant in line with those proposed,108 with low clotting
stimulation (low tissue factor) to give way to expression of
the endogenous clotting status and to express effects of TAFI,
and to add t-PA to the test. It is suggested to explore this type
of approach and perform studies to evaluate its validity to
possibly reach high efﬁcacy in risk analysis.
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